At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
|Articles|March 2, 2004
- Pharmaceutical Technology-03-02-2004
- Volume 28
- Issue 3
Pharmaceutical Pricing and Healthcare Access
Author(s)Jill Wechsler
Healthcare coverage and costs remain prime concerns for FDA as the number of uninsured Americans continues to grow.
Advertisement
Articles in this issue
over 22 years ago
The Effect of Buffers on Protein Conformational Stabilityover 22 years ago
Packaging Helps Protect Temperature-Sensitive Productsover 22 years ago
Resealed Erythrocytes: A Reviewover 22 years ago
Pharma Industry Drives Innovation in Barrier/Isolation Designover 22 years ago
Connecting Clinical Trial Management to Pharmaceutical Manufacturingover 22 years ago
March 2003over 22 years ago
Stakes Getting Higher for ContractorsAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Can AI Agents Satisfy CGMP Documentation Requirements?
3
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
4
PharmTech AI Pulse Check: Fixing AI Slop at the Source
5